Currently,several stakeholders in the pharmaceutical industry are actively engaged in theefforts to develop leads based on natural and synthetic derivatives ofpsychedelic substances. Further, experts believe that psychedelics, atappropriate doses, can be used to address some of the serious psychologicalimplications associated with the COVID-19 pandemic.
To order this 250+page report, which features 120+ figures and 135+ tables, please visit this - https://www.rootsanalysis.com/reports/global-psychedelic-therapeutics-market.html
The overUSD 6.5 billion (by 2030) financial opportunity within the psychedelictherapeutics market has been analyzed across the following segments:
§ Target DiseaseIndication
- Anxiety and Depression
- Trauma
- Pain Disorder
- Sleep related Disorder
§ Originof Psychedelic Substance
- Natural
- Synthetic
§ Typeof Psychedelic Substance
- Gamma-hydroxybutyrate
- Ketamine
- MDMA
- Psilocybin
§ Routeof Administration
- Oral
- Intranasal
- Sublingual
§ KeyGeographies
- North America
- Europe
- Asia-Pacific
The GlobalPsychedelic Therapeutics Market, 2020-2030” report features thefollowing companies, which we identified to be key players in this domain:
§ CelonPharma
§ iXBiopharma
§ MAPSPublic Benefit
§ MindMed
§ JanssenPharmaceuticals
§ JazzPharmaceutical
Table of Contents
1. Preface
2. Executive Summary
3. Introduction
4. Market Landscape:Psychedelic Therapeutics
5. Company Profiles
6. Clinical Trial Analysis
7. Clinical Trial Site Analysis
9. Key Opinion Leader (KOL)Analysis
8. Academic Grants Analysis
10. Partnerships andCollaborations
11. Mergers and Acquisitions
12. Market Forecast andOpportunity Analysis
13. Concluding Remarks
14. Executive Insights
15. Appendix 1: Tabulated Data
16. Appendix 2: List ofCompanies and Organizations
To purchase a copy,please visit https://www.rootsanalysis.com/reports/view_document/immune-checkpoint-inhibitors/303.html
Contact Details
Gaurav Chaudhary
+1 (415) 800 3415
gaurav.chaudhary@rootsanalysis.com
